Blockade of STAT3/IL-4 overcomes EGFR T790M- cis -L792F-induced resistance to osimertinib via promoting M2 macrophages polarization.

Yiting Sun,Yuanyuan Ma,Zhihua Tian,Xijuan Liu,Xiang Yan,Wei Zhao,Jie Wang,Zhijie Wang
DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.e20552
IF: 45.3
2022-06-01
Journal of Clinical Oncology
Abstract:e20552 Background: Missense alteration at EGFR L792F emerges after osimertinib resistance in patients with non-small cell lung cancer (NSCLC). However, its mechanism has not been sufficiently clarified. We aimed to explore the critical molecular events and coping strategies in osimertinib resistance due to acquired L792F mutation. Methods: Circulating tumor DNA-based sequencing data of 1382 patients with osimertinib resistance were collected to illustrate the prevalence of L792F mutation. Sensitivity to osimertinib was tested with constructed 19Del/T790M-cis-L792F mutations and control cell lines in vitro and in vivo. The correlation and linked pathways between M2 macrophage polarization and EGFR 19Del/T790M-cis-L792F-induced osimertinib resistance were investigated. Also, possible interventions to suppress osimertinib resistance by targeting IL-4 or STAT3 were explored. Results: The concomitant EGFR L792 was identified as an independent mutation following the acquisition of T790M after osimertinib resistance, in that 5 of the 946 patients with osimertinib resistance harbored EGFR L792F- cis mutation. Transfected EGFR 19Del/T790M-cis-L792F in cell lines had decreased sensitivity to osimertinib and enhanced infiltrating macrophage with M2 polarization. Silico analyses confirmed the role of M2 polarization in osimertinib resistance induced by EGFR T790M-cis-L792F mutations. The upregulated phosphorylation of STAT3 Tyr705 and downstream expression and secretion of IL-4 induced M2 polarization. Furthermore, blockade of STAT3/IL-4 (SH-4-54 or dupilumab) suppressed M2 macrophage polarization and regressed tumor sensitivity to osimertinib and delayed tumor growth. Conclusions: Our results provided solid evidence of EGFR T790M-cis-L792F mutation as a factor inducing osimertinib resistance. Targeting EGFR T790M-cis-L792F/STAT3 Tyr705/IL-4 pathway could be a potential strategy to suppress osimertinib resistance in NSCLC.
oncology
What problem does this paper attempt to address?